FDAANN / ANNUAL
No resting orders on this market.
Important information: The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
Resolves Yes if the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.